Granted Patent
B2
US 12,286,432 · App. 18/203,776 · Granted Apr 29, 2025
Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
Assignee:
OcuTerra Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Claims (22)
1. A compound represented by:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound is
3. A compound represented by
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 3 , wherein the compound is
5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
6. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or excipient.
7. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier or excipient.
8. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier or excipient.
9. A method of treating fibrosis in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 to treat the fibrosis.
10. A method of treating fibrosis in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 2 to treat the fibrosis.
11. A method of treating fibrosis in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 3 to treat the fibrosis.
12. A method of treating fibrosis in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 4 to treat the fibrosis.
13. The method of claim 9 , wherein the fibrosis is a fibrosis of the liver, kidney, intestine, heart, or lung.
14. The method of claim 10 , wherein the fibrosis is a fibrosis of the liver, kidney, intestine, heart, or lung.
15. The method of claim 11 , wherein the fibrosis is a fibrosis of the liver, kidney, intestine, heart, or lung.
16. The method of claim 12 , wherein the fibrosis is a fibrosis of the liver, kidney, intestine, heart, or lung.
17. A method of treating a disease or condition selected from macular degeneration, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinopathy of prematurity, or macular edema following retinal vein occlusion in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 to treat the disease or condition.
18. A method of treating a disease or condition selected from macular degeneration, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinopathy of prematurity, or macular edema following retinal vein occlusion in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 2 to treat the disease or condition.
19. A method of treating a disease or condition selected from macular degeneration, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinopathy of prematurity, or macular edema following retinal vein occlusion in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 3 to treat the disease or condition.
20. A method of treating a disease or condition selected from macular degeneration, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinopathy of prematurity, or macular edema following retinal vein occlusion in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 4 to treat the disease or condition.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 12, 2026
From: OCUTERRA THERAPEUTICS, INC. (FORMERLY KNOWN AS SCIFLUOR LIFE SCIENCES, INC.)
To: FELIQS CORPORATION
Reel/Frame 073443/0692 →
CHANGE OF NAME
Recorded Jul 31, 2023
From: SCIFLUOR LIFE SCIENCES, INC.
To: OCUTERRA THERAPEUTICS, INC.
Reel/Frame 064435/0061 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 31, 2023
From: ASKEW, BEN C.; FURUYA, TAKERU
To: SCIFLUOR LIFE SCIENCES, INC.
Reel/Frame 064435/0341 →
Continuity (6)
Provisional Application
62118303
· Feb 19, 2015
References Cited (183)
US 4927266A
· Sugiura et al.
· 1990
[cited by applicant]
US 4937266A
· Tomikawa et al.
· 1990
[cited by applicant]
US 5374660A
· Murad et al.
· 1994
[cited by applicant]
US 5501969A
· Hastings et al.
· 1996
[cited by applicant]
US 5571846A
· Murad et al.
· 1996
[cited by applicant]
US 5645839A
· Chobanian et al.
· 1997
[cited by applicant]
US 5736357A
· Bromme et al.
· 1998
[cited by applicant]
US 6017926A
· Askew et al.
· 2000
[cited by applicant]
US 6066648A
· Duggan et al.
· 2000
[cited by applicant]
US 6117445A
· Neely
· 2000
[cited by applicant]
US 6139847A
· Chobanian et al.
· 2000
[cited by applicant]
US 6211184B1
· Duggan et al.
· 2001
[cited by applicant]
US 6268342B1
· Culler et al.
· 2001
[cited by applicant]
US 6268378B1
· Duggan et al.
· 2001
[cited by applicant]
US 6291503B1
· Schoop et al.
· 2001
[cited by applicant]
US 6297249B1
· Duggan et al.
· 2001
[cited by applicant]
US 6303126B1
· Nakamura et al.
· 2001
[cited by applicant]
US 6407241B1
· Jensen et al.
· 2002
[cited by applicant]
US 6410526B1
· Duggan et al.
· 2002
[cited by applicant]
US 6426353B1
· Arison et al.
· 2002
[cited by applicant]
US 6472403B2
· Duggan et al.
· 2002
[cited by applicant]
US 6500835B2
· Fukami et al.
· 2002
[cited by applicant]
US 6664227B1
· Wynn et al.
· 2003
[cited by applicant]
US 7056909B2
· Wang
· 2006
[cited by applicant]
US 8901144B2
· Askew et al.
· 2014
[cited by applicant]
US 9266884B2
· Askew et al.
· 2016
[cited by applicant]
US 9518053B2
· Askew et al.
· 2016
[cited by applicant]
US 9572801B2
· Askew et al.
· 2017
[cited by applicant]
US 9593114B2
· Askew et al.
· 2017
[cited by applicant]
US 9717729B2
· Askew et al.
· 2017
[cited by applicant]
US 9790222B2
· Askew et al.
· 2017
[cited by applicant]
US 9802933B2
· Askew et al.
· 2017
[cited by applicant]
US 20010053853A1
· Askew et al.
· 2001
[cited by applicant]
US 20020016461A1
· Albers et al.
· 2002
[cited by applicant]
US 20020037889A1
· Duggan et al.
· 2002
[cited by applicant]
US 20020040030A1
· Coleman et al.
· 2002
[cited by applicant]
US 20020040039A1
· Hartman et al.
· 2002
[cited by applicant]
US 20020049224A1
· Arison et al.
· 2002
[cited by applicant]
US 20040053968A1
· Hartman et al.
· 2004
[cited by applicant]
US 20050004199A1
· Hartman et al.
· 2005
[cited by applicant]
US 20050043344A1
· Boys et al.
· 2005
[cited by applicant]
US 20060030581A1
· DeBusi et al.
· 2006
[cited by applicant]
US 20070117849A1
· Goodman et al.
· 2007
[cited by applicant]
US 20190225609A1
· Askew et al.
· 2019
[cited by applicant]
US 20190263810A1
· Askew et al.
· 2019
[cited by applicant]
US 20210246132A1
· Askew et al.
· 2021
[cited by applicant]
CN 1284955A
· 2001
[cited by applicant]
CN 1589145A
· 2005
[cited by applicant]
EP 1040098A1
· 2000
[cited by applicant]
JP 2007507440A
· 2007
[cited by applicant]
WO WO199613523A1
· 1996
[cited by applicant]
WO WO199930709A1
· 1999
[cited by applicant]
WO WO199931061A1
· 1999
[cited by applicant]
WO WO199931099A1
· 1999
[cited by applicant]
WO WO200147867A1
· 2001
[cited by applicant]
WO WO200187840A1
· 2001
[cited by applicant]
WO WO200207730A1
· 2002
[cited by applicant]
WO WO2004058254A1
· 2004
[cited by applicant]
WO 2005039547A1
· 2005
[cited by applicant]
WO WO2011060395A1
· 2011
[cited by applicant]
WO WO2011150156A2
· 2011
[cited by applicant]
WO WO2013000909A1
· 2013
[cited by applicant]
WO WO2014124302A1
· 2014
[cited by applicant]
Abdollahi et al., “Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy,” Clin Cancer Res. Sep. 1, 2005;11(17):6270-9.
[cited by applicant]
Adams J. et al., “Structure Activity Relationships of av Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents”,
[cited by applicant]
Ali, Y. et al., “Industrial perspective in ocular drug delivery,” Adv. Drug Deliv. Rev. 2006, 58, 1258-1268.
[cited by applicant]
Ando, M. et al., “Facile One-Pot Synthesis of N-Difluoromethyl-2-pyridone Derivatives”,
[cited by applicant]
Bourges et al., “Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles,” Invest Ophthalmol Vis Sci. Aug. 2003;44(8):3562-9.
[cited by applicant]
Bradshaw et al., “Synthesis of 5-hydroxy-2,3,4,5-tetrahydro-[1H]-2-benzazepin-4-ones: selective antagonists of muscarinic (M3) receptors,” Org Biomol Chem. Jun. 21, 2008;6(12):2138-57.
[cited by applicant]
Brinkmann et al., “Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis,”
[cited by applicant]
Bunz, “The Cancer Gene Theory,”
[cited by applicant]
Campochiaro, P.A., et al., “Reduction of Diabetic Macular Edema by Oral Administration of the Kinase Inhibitor PKC412,”
[cited by applicant]
Cao, F., et al. “Zn—Al—NO3-layered double hydroxides with intercalated diclofenac for ocular delivery,”
[cited by applicant]
Chavakis, E. et al., “Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides”,
[cited by applicant]
Chen, H. et al., “FICA and BSEP defects in Taiwanese patients with chronic intrahepatic cholestasis with low y-glutamyltranspeptidase levels”,
[cited by applicant]
Chu et al., “Interaction of West Nile Virus with avb3 Integrin Mediates Virus Entry into Cells”, The Journal of Biological Chemistry, vol. 279, No. 52, p. 54533-54541 (2004).
[cited by applicant]
Coleman, P. et al., Nonpeptide avB3 Antagonists. Part II: Discovery and Preclinical Evaluation of Potent avB3 Antagonists for the Prevention and Treatment of Osteoporosis, J. Med Chem. 2004, 47, 4829-4837.
[cited by applicant]
Coughlin et al., “Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy”,
[cited by applicant]
D'Ambrosio et al., “Chemokine receptors in inflammation: an overview,”
[cited by applicant]
Data from the National Cancer Institute (http://www.cancer.gov/) (Downloaded May 29, 2014).
[cited by applicant]
Diebold, Y. et al., “Applications of nanoparticles in ophthalmology,”
[cited by applicant]
Dorrell, M., “Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis,”
[cited by applicant]
Doukas, J., et al., “Topical Administration of a Multi-Targeted Kinase Inhibitor Suppresses Choroidal Neovascularization and Retinal Edema,”
[cited by applicant]
Duan et al., “Association of αvl33 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells,”
[cited by applicant]
Felding-Habermann, “Involvement of tumor cell integrin αvl33 in hematogenous metastasis of human melanoma cells,”
[cited by applicant]
Freund, K. et al., “Age-related Macular Degeneration and Choroidal Neovascularization” Am. J. Ophthalmol. 1993, 115(6), 786-791.
[cited by applicant]
Friedlander, M. et al., “Involvement of integrins avB3 and avB5 in ocular neovascular diseases”,
[cited by applicant]
Friedlander, P.,
[cited by applicant]
Fu, Y., et al., “Angiogenesis Inhibition and Choroidal Neovascularization Suppression by Sustained Delivery of an Integrin Antagonist, EMD478761,”
[cited by applicant]
Gaudana, R. et al., “Recent Perspectives in Ocular Drug Delivery”,
[cited by applicant]
Hahm, K. et al., “avB6 Integrin Regulates Renal Fibrosis and Inflammation in Alport House”,
[cited by applicant]
Hallinan, E.A. et al., “N-Substituted dibenzoxazepine as analgesic PGE2 antagonists,”
[cited by applicant]
Hariharan et al., “Assessment of the biological and pharmacological effects of the αvl35 and αvl35 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors,”
[cited by applicant]
Haynes et al., Bone Resorption in,
[cited by applicant]
Henderson, N. et al., “Targeting of av integrin identifies a core molecular pathway that regulates fibrosis in several organs”,
[cited by applicant]
Hodlvala-Dilke, “av63 integrin and angiogenesis: a moody integrin in a changing Environment”, Current Opinion in Cell Biology, 20:514-519 (2008).
[cited by applicant]
Hutchison, John H., et al., Nonpeptide αvβ3 Antagonists. 8. In Vitro and In Vivo Evaluation of a Potent αvβ3 Antagonist for the Prevention and Treatment of Osteoporosis, J. Med. Chem., 46:4790-4798 (2003).
[cited by applicant]
Hynes, “IIntegrins: bidirectional, allosteric signaling machines,” Cell. Sep. 20, 2002;110(6):673-87.
[cited by applicant]
Jacot, J.L. et al., “Potential Therapeutic Roles for Inhibition of the P13K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy,”
[cited by applicant]
Jubb et al., “Predicting benefit from antiangiogenic agents in malignancy”,
[cited by applicant]
Judge et al., “Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment,”
[cited by applicant]
Kamizuru, H. et al., “Monoclonal Antibody-Mediated Drug Targeting to Choroidal Neovascularization in the Rat”,
[cited by applicant]
Kaur, H. et al., “Niosomes: A Novel Drug Delivery System”,
[cited by applicant]
Kern, T.S., et al., “Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology,”
[cited by applicant]
Klein, M. et al., “Heredity and Age-Related Macular Degeneration, Observations in Monozygotic Twins”
[cited by applicant]
Klein, R. et al., “The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy,”
[cited by applicant]
Koelink et al., “Targeting chemokine receptors in chronic inflammatory diseases: An extensive review,”
[cited by applicant]
Kumar, C. et al., “Biochemical Characterization of the Binding of Echistatin to Integrin avB3 Receptor”,
[cited by applicant]
Kuppen et al., “Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer,”
[cited by applicant]
Linderman, R.J., “Oxidation of Fluoroalkyl-Substituted Carbinols by the Dess-Martin Reagent,”
[cited by applicant]
Lissoni et al., “Biotherapy with the pineal hormone melatonin plus aloe and myrrh tincture in untreatable metastatic cancer patients as an essence therapy of cancer,”
[cited by applicant]
Lorger et al., Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain,
[cited by applicant]
Luna, J. et al., “Antagonists of Integrin avB3 Inhibit Retinal Neovascularization in a Murine Model”,
[cited by applicant]
Luo et al., “Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction,”
[cited by applicant]
Lyons et al., “Integrins in metastatic adenoid cystic carcinoma,”
[cited by applicant]
Marelli et al., “Tumor targeting via integrin ligands,”
[cited by applicant]
Max et al., “Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas,”
[cited by applicant]
Mcdermott et al., “Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology”,
[cited by applicant]
Meissner, R.S. et al., “Nonpeptide αvβ3 Antagonists. Part 2: Constrained Glycyl Amides Derived from the RGD Tripeptide”,
[cited by applicant]
Millauer, B., et al., “Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types in Vivo”,
[cited by applicant]
Moors et al. Journal of Medicinal Chemistry (2011), 54(17), 6098-6105.
[cited by applicant]
Mousa, “Cell Adhesion Molecules: Potential Therapeutic & Diagnostic Implications,”
[cited by applicant]
Muller et al., Antiviral Strategies in, Antiviral Strategies 1-24, 4 (H.-G. Krausslich et al., eds., 2009).
[cited by applicant]
Murphy, M.G., et al., “Effect of L-000845704, an αvβ3 Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women,”
[cited by applicant]
Nahm, S., et al., “N-methoxy-n-methyl amides as effective acylating agents,”
[cited by applicant]
Noutsias M. et al. “Human Coxsackie-Adenovirus Receptor is Colocalized with ayb3 and avb5 on the Cardiomyocyte Sarcolemma and Upregulated in Dilated Cardiomyopathy Implications for Cardiotropic Viral Infections”, Circul…
[cited by applicant]
Parry C. et al. “Herpes simplex virus type 1 glycoprotein H binds to aVB3 integrins”, Journal of General Virology, vol. 86, p. 7-10 (2005).
[cited by applicant]
Pialat, A. et al., “Oxidative para-Triflation of Acetanilides,”
[cited by applicant]
Poynard, T. et al., “Natural history of liver fibrosis progression in patients with chronic hepatitis C”,
[cited by applicant]
Prasasya et al., “Analysis of cancer signaling networks by systems biology to develop therapies”,
[cited by applicant]
Rabinow, Barrett E., “Nanosuspensions in Drug delivery,”
[cited by applicant]
Registry No. 227963-76-0 (Entered STN Jul. 16, 1999).
[cited by applicant]
Reinmuth et al., “av133 Integrin Antagonist S247 Decreases Colon Cancer Metastasis and Angiogenesis and Improves Survival in Mice”, Cancer Research, 63:2079-2087 (2003).
[cited by applicant]
Riecke, B. et al. “Topical Application of Integrin Antagonists Inhibit Proliferative Retinopathy,”
[cited by applicant]
Rognoni, E. et al., “Kindlin-1 controls Wnt and TGF-B availability to regulate cutaneous epithelial stem cell proliferation”,
[cited by applicant]
Rolli et al., “Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells,”
[cited by applicant]
Rowe, Raymond C., “Handbook of Pharmaceutical Excipients”, Fifth Edition, Pharmaceutical Press and American Pharmacists Association (2006).
[cited by applicant]
Santulli et al., “Evaluation of the anti-angiogenic properties of the new selective av[33 integrin antagonist RGDechiHCit”, Journal of Translational Medicine, 9:1-10 (2011.
[cited by applicant]
Santulli, R. et al., “Studies with an Orally Bioavailable ?v Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats,” The Journ…
[cited by applicant]
Sato, I. et al., “Enantioselective Synthesis of Substituted 3-Quinolyl Alkanols and Their Application to Asymmetric Autocatalysis,”
[cited by applicant]
Sawyers, “The Cancer Biomarker Problem”,
[cited by applicant]
Seebach, D. et al., “Total Synthesis of Myxovirescin, 1 Strategy and Construction of the Southeastern Part [O(1)-C(14)]”, Liebigs Ann. Chem., pp. 701-717 (1994).
[cited by applicant]
Sondej, S.C. et al., “Gem-Difluoro Compounds: A Convenient Preparation from Ketones and Aldehydes by Halogen Fluoride Treatment of 1,3-dithiolanes,” J. Org. Chem., 51:3508-3513 (1986).
[cited by applicant]
Soussi, “p53 Antibodies in the Sera of Patients with Various Types of Cancer: A Review,”
[cited by applicant]
Speicher, M.A. et al. “Pharmacologic therapy for diabetic retinopathy,” Expert Opin Emerging Drugs, 8(1):239-250 (2003).
[cited by applicant]
Stragies, R. et al. “Design and Synthesis of a New Class of Selective Integrin α5β1 antagonists”,
[cited by applicant]
Stupp et al., “Integrin Inhibitors Reaching the Clinic”,
[cited by applicant]
Summerford C. et al. “avB5 integrin: a co-receptor for adeno-associated virus type 2 infection”, Nature Medicine, vol. 5, No. 1, p. 78-82 (1999).
[cited by applicant]
Surendranan, K. et al., “A role for Wnt-4 in renal fibrosis”,
[cited by applicant]
Sutherland et al., “Management of Chronic Obstructive Pulmonary Disease,”
[cited by applicant]
Takagi, H. et al., “Role of Vitronectin Receptor-Type Integrins and Osteopontin in Ischemia-Induced Retinal Neovascularization,”
[cited by applicant]
Takahashi, K et al. “Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib,”
[cited by applicant]
Takayama et al., “The Relationship Between Bone Metastasis from Human Breast Cancer and Integrin αv133 Expression,”
[cited by applicant]
Vandamme, Th.F., “Microemulsions as ocular drug delivery systems: recent developments and future challenges,”
[cited by applicant]
Wagh, V.D. et al. “Niosomes as ophthalmic drug delivery systems: a review,”
[cited by applicant]
Wang et al., “Mathematical modeling in cancer drug discovery,”
[cited by applicant]
Wang, W. et al. “The Antiangiogenic Effects of Integrin α531 Inhibitor (ATN-161) In Vitro and In Vivo,”
[cited by applicant]
Ward et al., “Inflammation and ?v133 Integrin,” American Journal of Respiratory and Critical Care Medicine, 85:5-6 (2012).
[cited by applicant]
Wayner, E. et al., “Integrins avB5 and avB6 Contribute to Cell Attachment to Vitronectin but Differentially Distribute on the Cell Surface”, J. Cell. Biol. 1991, 113(4), 919-929.
[cited by applicant]
Wilder R. et al. “Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases”, Ann Rheum Dis, vol. 61, Suppl. II, p. 96-99 (2002).
[cited by applicant]
Williams, R. et al. “Epidemiology of diabetic retinopathy and madular oedema: a review,”
[cited by applicant]
Yang, X.M., “Role of P13K/Akt and MEK/ERK in Mediating Hypoxia-Induced Expression of HIF-1? and VEGF in Laser-Induced Rat Choroidal Neovascularization,” Investigative Ophthalmology & Visual Science, 50(4):1873-1879 (200…
[cited by applicant]
Yanni, S.E. et al., “The effects of nepafenac and amfenac on retinal angiogenesis,” Elsevier, Brain Research Bulletin, 81:310-319 (2010).
[cited by applicant]
Yasuda, N., et al., “An Efficient Synthesis of an αvβ3 Antagonist,”
[cited by applicant]
Yasukawa, T, et al. “Inhibition of experimental choroidal neovascularization in rats by an αv-integrin antagonist,” Current Eye Research, 28(5):359-366 (2004).
[cited by applicant]
Zarbin, M.A. “Current Concepts in the Pathogenesis of Age-Related Macular Degeneration”, Arch. Ophthalmol., 122:598-614 (2004).
[cited by applicant]
Zhao et al., Journal of Physical Chemistry B (2009), 113(17). 5929-5937.
[cited by applicant]
Zhou, Hong-Yan et al., “Nanoparticles in the ocular drug delivery,”
[cited by applicant]